Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
700.00    -10.00 (-1.41%)
Bid:
700.00
Ask:
706.00
Spread: 6.00 (0.857%)
Market Cap: £346.93m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

Trading Update and Interim Dividend

22 Jan 2026 07:00

RNS Number : 8539P
Elixirr International PLC
22 January 2026
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.

 

22 January 2026

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or "Group")

Trading Update and Interim Dividend

Strong revenue and EBITDA growth, continued strategic execution and increased dividend

Elixirr International plc (ELIX.L), an established, global award-winning challenger consultancy, is pleased to provide an update on trading and details of its interim dividend for the year ended 31 December 2025 ("FY 25").

Trading Update

Subject to audit, FY 25 revenue is expected to meet or exceed market expectations of £149 million, reflecting continued momentum across the Group. In particular, the Group delivered record cross-sell revenue, as Partners leveraged an expanded capability set and broader combined networks to deepen existing client relationships.

Subject to audit, FY 25 Adjusted EBITDA margin is expected to meet or exceed market expectations of 28.1% - 29.2%, underpinned by operating leverage, disciplined cost control, the continued stretch of revenue per Partner and the acquisition of TRC Advisory, LLC.

Client quality continued to strengthen, with the number of 'gold clients' (generating £1m+ annual revenue) increasing to 34, up from 27 in FY 24. This reflects the combined impact of hiring high-quality Partners, making differentiated acquisitions, promoting talent from within, and expanding the scope and depth of work delivered to long-standing clients.

The Group continued to generate strong cash flows during the period. Year-end net debt of £24.1 million (excluding capitalised office leases) was approximately £7 million more favourable to market expectations, demonstrating the cash generative nature of the business and the Group's strong cash discipline.

Progress across Elixirr's four-pillar growth strategy of stretching existing Partners, promoting from within, hiring new Partners and acquiring businesses continues to deliver against the Group's growth ambitions. The Group remains active in its acquisition pipeline and continues to explore value-accretive acquisitions, while maintaining a disciplined approach to capital allocation.

The Board is pleased to note that the Group's unaudited FY 25 performance continues Elixirr's consistent delivery against the Rule of 40, with the combined total of revenue growth and Adjusted EBITDA margin exceeding 40%, as has been achieved in every year since the AIM IPO in FY 20. In both FY 24 and FY 25, the Group also achieved the Rule of 50. The Board believes this consistent performance supports its ambition for Elixirr to enter the FTSE 250 index within the next 12 months.

The Group has also entered FY 26 with a record amount of revenue contracted for the year as measured on the first day of a new financial year.

The Group will announce its audited full year FY 25 results on 20 April 2026.

Interim Dividend

The Company is declaring an interim dividend for FY 25 (the "Dividend") of 7.6p per Ordinary Share, representing an increase of 21% on the FY 24 interim dividend per share.

The Dividend will be payable to shareholders on the register as at 30 January 2026 and has an associated ex-dividend date of 29 January 2026. The Dividend of approximately £3.8 million in total will be paid to shareholders on 24 February 2026 and funded from the Company's operating cash flow.

Stephen Newton, Founder and Chief Executive Officer, commented:

"This performance reflects the deliberate way we are building Elixirr - expanding what we can do for clients, deepening relationships and scaling the business without compromising discipline. FY 25 was a great year for us, and we are excited about what FY 26 will bring. Our aim is to be close to or in the FTSE 250 by the end of the year. Interestingly, if we were valued at the same EV/EBITDA multiple as our initial AIM IPO in 2020, we already would be. We will therefore keep delivering until we are!"

 

Enquiries:

For enquiries, please refer to the Company's Investor Contacts page:

https://www.elixirr.com/investors/investor-contacts

Elixirr International plc +44 (0)20 7220 5410  

Stephen Newton, Chief Executive Officer

Graham Busby, Deputy Chief Executive Officer

Nicholas Willott, Chief Financial Officer and Company Secretary

investor-relations@elixirr.com

Cavendish Capital Markets Ltd (Broker) +44 (0)20 7220 0500

Stephen Keys, Callum Davidson, Isaac Hooper (Corporate Finance),

Sunila de Silva (ECM)

 

About Elixirr International plc

Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies. Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr was quoted on the AIM market of the London Stock Exchange in 2020 and listed on the Main Market of the London Stock Exchange in July 2025. In addition to strong organic growth, Elixirr has acquired eight boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam, Hypothesis and TRC Advisory - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKDBQOBKDKDB
Date   Source Headline
2nd Jun 20269:49 amRNSNotice of AGM and Dividend Timetable
20th May 20267:00 amRNSIssue of Equity - TRC Contingent Consideration
14th May 20268:38 amRNSHolding(s) in Company
29th Apr 20263:59 pmRNSHolding(s) in Company
29th Apr 202611:18 amRNSPublication of 2025 Annual Report
28th Apr 20265:59 pmRNSResult of Secondary Placing
28th Apr 20264:35 pmRNSProposed Secondary Placing
20th Apr 20267:00 amRNSResults for the year ended 31 December 2025
10th Apr 20267:00 amRNSHolding(s) in Company
27th Mar 20267:00 amRNSNotice of FY 25 Investor Presentation
23rd Mar 20267:00 amRNSGrant of Share Options
19th Mar 202610:09 amRNSDirector/PDMR Shareholding
27th Feb 202610:26 amRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSDirector/PDMR Shareholding
2nd Feb 20267:00 amRNSAcquisition of Kvadrant Consulting A/S
30th Jan 20267:00 amRNSAppointment of Non-Executive Director
22nd Jan 20267:00 amRNSTrading Update and Interim Dividend
9th Jan 20264:37 pmRNSPDMR Shareholding
25th Sep 20258:08 amRNSDirector/PDMR Shareholding
22nd Sep 20257:01 amRNSInterim Results
22nd Sep 20257:00 amRNSAcquisition of TRC Advisory, LLC
18th Sep 20253:28 pmRNSIncrease in Debt Facilities to Support M&A
17th Sep 20257:00 amRNSNotice of H1 25 Investor Presentation
15th Sep 20257:00 amRNSMove from SETSqx to SETS
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSChange of Adviser
1st Jul 20258:00 amRNSReadmission - Elixirr International Plc
1st Jul 20257:00 amRNSAdmission to Main Market
26th Jun 20256:00 pmRNSElixirr International
24th Jun 20253:44 pmRNSPublication of Prospectus
24th Jun 202512:39 pmRNSResult of AGM
10th Jun 20257:00 amRNSGrant of Share Options
30th May 20257:00 amRNSMain Market Update & Capital Markets Day
29th May 20253:58 pmRNSPDMR Dealings and EBT Transfers
29th May 20257:00 amRNSPosting of Annual Report and Accounts
21st May 20257:00 amRNSCapital Markets Day
8th May 202512:21 pmRNSHoldings in Company – Employee Benefit Trust
28th Apr 20257:00 amRNSFinal Results
11th Mar 20257:00 amRNSNotice of FY24 Investor Presentation
18th Feb 20257:00 amRNSTrading Update
22nd Jan 20257:00 amRNSGrant of Restricted Share Awards
17th Jan 20251:40 pmRNSPurchase of Shares by Employee Benefit Trust
16th Jan 20253:05 pmRNSDirector/PDMR Shareholding
13th Jan 20258:06 amRNSBoard Appointment
6th Jan 20257:00 amRNSAppointment of Joint Broker
20th Dec 20244:20 pmRNSDirector/PDMR Shareholding
20th Dec 20247:00 amRNSInterim Dividend
10th Dec 20247:00 amRNSBoard Changes
25th Nov 20247:00 amRNSChange of Adviser
31st Oct 20247:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.